Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
Partner Therapeutics takes on Sanofi's immunostimulant. Novartis transitions struggling Arzerra for compassionate use only outside the US, with compensation to Genmab, while Shire licenses I.V. immunoglobulin candidate from AB Biosciences.
You may also be interested in...
Deal Snapshot: In acquiring its fellow San Diego firm for an estimated deal value of up to $516m, Ligand picks up protein-expression technology, revenue-driving partnerships and the potential for more.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Torrent Pharma has made “substantial progress” with the integration of the acquired Unichem business, turning around key brands and building momentum in field force productivity. Rationalization efforts are expected to drive additional cost savings going forward.